Mana.bio
Mana.bio applies machine learning to LNP design and disclosed a 2026 ASGCT presentation on progress toward in vivo CAR-T. The accessible material supports delivery-platform research; a named therapeutic candidate, clinical initiation, and patient efficacy were not verified.
Corporate information
- Company entity
- Mana.bio
- Headquarters / principal office
- Tel Aviv, Israel (announcement dateline; registered headquarters not independently confirmed) ↗
- Founded
- Not verified
- Ownership / capital status
- PrivateSeed financing disclosed in 2023 ↗
- Official corporate reference
- https://www.mana.bio/news ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2023-10-10 · Seed · US$19.5 million ↗
Historical financing located in this review; no claim that no later round occurred.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Mana.bio applies machine learning to LNP design and disclosed a 2026 ASGCT presentation on progress toward in vivo CAR-T. The accessible material supports delivery-platform research; a named therapeutic candidate, clinical initiation, and patient efficacy were not verified.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.